Cancer clinical trials in the region Provence-Alpes-Côte d'Azur

212 currently recruiting clinical trials

If you are a doctor and would like find matching clinical trials for you patients, create an account or log in

If you are a patient and would like to know if you may participate in a clinical trial, please consult your doctor so that he can send your file to a matching trial

Early Access Lung cancer

Accès précoce pré-AMM– RYBREVANT 350 mg

NSCLC (Non-Small Cell Lung Cancer) Locally Advanced Metastatic EGFR Targeted therapy

Systemic Treatment-Naive

Janssen

Early Access Lung cancer

Accès précoce pré-AMM– RYBREVANT 350 mg

NSCLC (Non-Small Cell Lung Cancer) Locally Advanced Metastatic EGFR None Systemic Treatment-Naive

Janssen

Early Access Lung cancer

Accès précoce pré-AMM– TAGRISSO (osimertinib)

NSCLC (Non-Small Cell Lung Cancer) Non-squamous NSCLC Locally Advanced EGFR None Chemotherapy Radiotherapy

AstraZeneca

Early Access Lung cancer

Accès précoce – OPDIVO (nivolumab)

NSCLC (Non-Small Cell Lung Cancer) Localized PDL1 Positive (1% <= X < 25%) PDL1 Positive (25% <= X < 50%) PDL1 Positive (>= 50%) None Systemic Treatment-Naive

ALK EGFR

Bristol-Myers Squibb

Early Access Lung cancer

Accès précoce pré-AMM– IMFINZI (durvalumab)

SCLC (Small Cell Lung Cancer) Localized Locally Advanced None Chemotherapy Radiotherapy Chemotherapy Radiotherapy

AstraZeneca

Phase 3 Lung cancer

#NCT06635824

[ABBIL1TY NSCLC-06] Essai visant à évaluer la supériorité de l'association ACASUNLIMAB et PEMBROLIZUMAB par rapport au DOCETAXEL, traitement de référence dans le cancer du poumon non à petites cellules

NSCLC (Non-Small Cell Lung Cancer) Metastatic PDL1 Positive (1% <= X < 25%) PDL1 Positive (25% <= X < 50%) PDL1 Positive (>= 50%) 1 2 Immunotherapy Chemotherapy

ALK BRAF EGFR KRAS G12C KRAS non G12C MET RET ROS-1 Systemic Treatment-Naive Car-T

Hôpital Sainte Musse (Toulon), Hôpital de la Timone AP-HM (Marseille), Institut Sainte Catherine (Avignon)

Genmab

Phase 3 Lung cancer

#NCT05555732

[TROPION-Lung07] DATOPOTAMAB DERUXTECAN et PEMBROLIZUMAB avec ou sans chimiothérapie au platine dans le cancer du poumon non à petites cellules

NSCLC (Non-Small Cell Lung Cancer) Non-squamous NSCLC Locally Advanced Metastatic PDL1 Negative (< 1%) PDL1 Positive (1% <= X < 25%) PDL1 Positive (25% <= X < 50%) None Systemic Treatment-Naive

Immunotherapy Bispecific T-cell engager antibodies Antibody Drug Conjugates (ADC) Immunotherapy Bispecific T-cell engager antibodies Antibody Drug Conjugates (ADC)

Hôpital Nord de Marseille (Marseille Cedex 20), Institut Paoli-Calmettes (Marseille), Institut Sainte Catherine (Avignon)

Daiichi Sankyo

Phase 3 Bladder / Urinary Tract / Urethral cancer

#NCT05024773

[PACLITAXEL-ACIDE HYALURONIQUE] Étude de l'ONCOFID-P-B

Non-invasive bladder cancer Urothelial carcinoma Localized 1 Immunotherapy

Systemic Treatment-Naive Systemic Treatment-Naive

Institut Paoli-Calmettes (Marseille)

Fidia Farmaceutici s.p.a.

Phase 3 Bladder / Urinary Tract / Urethral cancer

#NCT05911295

DISITAMAB VEDOTIN associé au PEMBROLIZUMAB vs chimiothérapie dans le cancer urothélial exprimant HER2 non traité auparavant

Invasive bladder cancer Upper excretory tract cancer Urethral cancer Urothelial carcinoma Locally Advanced Metastatic HER2 None Systemic Treatment-Naive

Immunotherapy

Institut Paoli-Calmettes (Marseille), Centre Antoine Lacassagne (Nice)

Seagen

Phase 3 Lymphoma CLL & Richter's syndrome

#NCT06428019

Étude visant à évaluer le risque de syndrome de lyse tumorale chez des patients atteints d'une Leucémie Lymphoïde Chronique non traitée, recevant du VENETOCLAX en association avec de l'OBINUTUZUMAB ou de l'ACALABRUTINIB

B cell lymphoma CLL (Chronic Lymphocytic Leukemia) Lymphocytic lymphoma > 60 ml/min 50-60 ml/min 30-50 ml/min Systemic Treatment-Naive

Centre Antoine Lacassagne (Nice)

Abbvie